nderstanding dyspnoea and exercise limitation in interstitial lung disease: the role of the peripheral chemoreflex (sub-study 1)

niversity of Auckland0 个研究点目标入组 15 人开始时间: 2021年1月19日最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Patients with fibrotic ILD (total lung capacity <80% predicted; FEV1/FVC > 0.7 and standard HRCT criteria (British Thoracic Society guidelines 2008)
•Aged 18 years or over

•More than 10 pack year smoking history
•Evidence of significant emphysema on CT scan
•Pulmonary Sarcoidosis
•Currently taking regular inhaled therapy for airways disease
•Serious co-morbidities that may contribute to dyspnoea and/or reduce exercise capacity including:
•oSevere respiratory disease other than ILD (e.g., chronic obstructive pulmonary disease)
•oPulmonary hypertension
•oSevere obesity (Body mass index > 35 kg/m2)
•oSevere orthopaedic impairment or rheumatologic disease
•oSignificant neurological disease
•oInfection or pyrexial illness
•Presence of any contraindications to cardiopulmonary exercise testing
•oUnstable angina or recent acute myocardial infarction
•oUncontrolled arrhythmias causing symptoms or haemodynamic compromise
•oSymptomatic severe aortic stenosis
•oOxygen saturation <85% at rest on room air
•oUncontrolled heart failure
•oUncontrolled asthma
•oUncontrolled thyroid disorders
•oMental impairment leading to inability to cooperate
•Current pregnancy
•Allergy or intolerance to dopamine.
•Current users of recreational drugs
•Current abusers of alcohol
•Inability to fully or appropriately provide consent (e.g., language issue, reading capability)
•Underlying medical conditions, which in the opinion of the Investigator place the participant at unacceptably high risk for participating in the study.

发起方

niversity of Auckland